Loss of heterozygosity at 3p in benign lesions preceding invasive breast cancer.

BACKGROUND Loss of heterozygosity (LOH) at chromosome 3p is one of the most common genetic abnormalities identified in human cancers and has occasionally been noted in benign proliferative lesions predisposing to breast cancer. If the frequency of LOH at 3p in benign proliferative lesions correlates with the subsequent development of breast cancer, it may be possible to develop powerful tools for molecular risk assessment based on this technology. MATERIALS AND METHODS Archival paraffin-embedded tissues from benign breast biopsies in five women who have developed breast cancer and three women who have not developed breast cancer were microdissected and allelotyped at 3p using six microsatellite markers. RESULTS No LOH was detected in the biopsies from women who have not developed breast cancer. For women developing breast cancer, the proportion of informative loci showing LOH in the benign proliferative lesions was 0.47 as compared to 0.57 for the associated breast cancers. There was no LOH detected in epithelial DNA from a fibroadenoma. Of 15 informative loci, 4 (27%) showed LOH in both the benign proliferative lesion and the associated cancer; however, the actual parental allele lost was different in three of these four cases. CONCLUSIONS These results suggest that there are specific patterns of genetic instability common to preneoplastic lesions and the breast cancers that subsequently develop even when the paired lesions are not clonally related. LOH analysis of benign breast epithelium may provide a tool for molecular risk assessment and a surrogate endpoint for breast cancer chemoprevention trials.

[1]  J. Minna,et al.  Comparison of molecular changes in lung cancers in HIV-positive and HIV-indeterminate subjects. , 1998, JAMA.

[2]  C. Schlötterer,et al.  Genome evolution: Are microsatellites really simple sequences? , 1998, Current Biology.

[3]  B. Agnarsson,et al.  High incidence of loss of heterozygosity at chromosome 17p13 in breast tumours from BRCA2 mutation carriers , 1998, Oncogene.

[4]  A. Jonasdottir,et al.  Chromosome imbalance at the 3p14 region in human breast tumours: high frequency in patients with inherited predisposition due to BRCA2. , 1998, European journal of cancer.

[5]  C. Yue,et al.  Allelic loss at BRCA1, BRCA2, and adjacent loci in relation to TP53 abnormality in breast cancer , 1997, Genes, chromosomes & cancer.

[6]  J. Minna,et al.  Analysis of the FHIT gene and FRA3B region in sporadic breast cancer, preneoplastic lesions, and familial breast cancer probands. , 1997, Cancer research.

[7]  J. Samet,et al.  Molecular damage in the bronchial epithelium of current and former smokers. , 1997, Journal of the National Cancer Institute.

[8]  G. Eichele,et al.  Embryonic lethality and radiation hypersensitivity mediated by Rad51 in mice lacking Brca2 , 1997, Nature.

[9]  A. Thor,et al.  Loss of Heterozygosity in Normal Tissue Adjacent to Breast Carcinomas , 1996, Science.

[10]  Å. Borg,et al.  The FHIT and PTPRG genes are deleted in benign proliferative breast disease associated with familial breast cancer and cytogenetic rearrangements of chromosome band 3p14. , 1996, Cancer research.

[11]  T. Glover,et al.  Precise localization of aphidicolin-induced breakpoints on the short arm of human chromosome 3. , 1995, Genomics.

[12]  J. Minna,et al.  Allele-specific chromosome 3p deletions occur at an early stage in the pathogenesis of lung carcinoma. , 1995, JAMA.

[13]  J. Eyfjörd,et al.  p53 abnormalities and genomic instability in primary human breast carcinomas. , 1995, Cancer research.

[14]  A. Gerdes,et al.  Chromosome abnormalities in benign hyperproliferative disorders of epithelial and stromal breast tissue , 1995, International journal of cancer.

[15]  B. Ljung,et al.  Deletion of two separate regions on chromosome 3p in breast cancers. , 1994, Cancer research.

[16]  L. Brinton,et al.  Breast cancer risk associated with proliferative breast disease and atypical hyperplasia , 1993, Cancer.

[17]  B. Vogelstein,et al.  A mammalian cell cycle checkpoint pathway utilizing p53 and GADD45 is defective in ataxia-telangiectasia , 1992, Cell.

[18]  G. Wahl,et al.  Wild-type p53 restores cell cycle control and inhibits gene amplification in cells with mutant p53 alleles , 1992, Cell.

[19]  M. Kastan,et al.  Wild-type p53 is a cell cycle checkpoint determinant following irradiation. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[20]  A. Tanigami,et al.  Allelotype of breast cancer: cumulative allele losses promote tumor progression in primary breast cancer. , 1990, Cancer research.

[21]  P. Devilee,et al.  At least four different chromosomal regions are involved in loss of heterozygosity in human breast carcinoma. , 1989, Genomics.

[22]  W. Dupont,et al.  Breast cancer risk associated with proliferative disease, age at first birth, and a family history of breast cancer. , 1987, American journal of epidemiology.

[23]  W D Dupont,et al.  Risk factors for breast cancer in women with proliferative breast disease. , 1985, The New England journal of medicine.